Recruiting
Phase 1
Phase 2

Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Sponsor:

Genmab

Code:

NCT05579366

Conditions

Platinum-Resistant Ovarian Cancer

Platinum Sensitive Ovarian Cancer (PSOC)

High Grade Epithelial Ovarian Cancer

High Grade Serous Ovarian Cancer

Primary Peritoneal Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Rina-S

Carboplatin

Bevacizumab

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-03. This information was provided to ClinicalTrials.gov by Genmab on 2025-03-25.